AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26937681 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regression model for predicting AHI.
Number of subjects: 135
Study 26937681 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision tree for discrimination between patients and normal subjects.
Number of subjects: 135
Study 26938078 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with first generation protease inhibitors (n = 23)
Number of subjects: 108
Study 26938078 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy with peginterferon and ribavirin (n = 21)
Number of subjects: 108
Study 26938078 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy with first generation protease inhibitors
Number of subjects: 108
Study 26938617 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 10
Study 26938769 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverting filter that undoes the effects of a 0.05 Hz single pole high-pass filter
Number of subjects: 1600
Study 26938769 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative, less strong inverting filters
Number of subjects: 1600
Study 26939629 — intervention group
Group type: EXPERIMENTAL
Intervention: Convection-enhanced delivery treatment of a therapeutic antibody
Number of subjects: 6
Study 26940080 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine administered as a bolus of 1 μg/kg over 10 min followed by 1 μg/kg/h infusion, with possible increase to 2 μg/kg/h if necessary.
Number of subjects: 19
Study 26940080 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dexmedetomidine dose and shorter sedation time for children younger than 1 year of age.
Number of subjects: 19
Study 26940214 — intervention group
Group type: EXPERIMENTAL
Intervention: High SBP
Number of subjects: 455
Study 26940214 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP
Number of subjects: 455
Study 26940214 — intervention group
Group type: EXPERIMENTAL
Intervention: BPRS-0
Number of subjects: 455
Study 26940214 — intervention group
Group type: EXPERIMENTAL
Intervention: BPRS-2
Number of subjects: 455
Study 26940383 — intervention group
Group type: EXPERIMENTAL
Intervention: Early home-based walking program implemented 1-month post-ICD implant.
Number of subjects: 301
Study 26940556 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 9500
Study 26940556 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 9500
Study 26940556 — intervention group
Group type: COMPARATOR
Intervention: Stable renal function
Number of subjects: 9500
Study 26940814 — intervention group
Group type: EXPERIMENTAL
Intervention: Home ventilation for complex children
Number of subjects: 90
Study 26940919 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium (CAC) scores >400
Number of subjects: 532
Study 26940919 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CAC scores in white women
Number of subjects: 532
Study 26940919 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical cardiovascular disease measures (CAC, carotid intimal medial thickness, stenosis, ankle brachial index)
Number of subjects: 532
Study 26940919 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia diagnosis prior to death
Number of subjects: 532
Study 26940919 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of dementia
Number of subjects: 532
Study 26940919 — intervention group
Group type: EXPERIMENTAL
Intervention: Deaths caused by CHD
Number of subjects: 532
Study 26940919 — intervention group
Group type: EXPERIMENTAL
Intervention: Deaths caused by dementia
Number of subjects: 532
Study 26941415 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased left atrial reservoir strain
Number of subjects: 308
Study 26941415 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial reservoir strain
Number of subjects: 308
Study 26941952 — intervention group
Group type: COMPARATOR
Intervention: Standard decision aid (control)
Number of subjects: 184
Study 26941952 — intervention group
Group type: EXPERIMENTAL
Intervention: Regret-incorporated decision aid (experimental)
Number of subjects: 184
Study 26942366 — intervention group
Group type: EXPERIMENTAL
Intervention: C sordellii presence
Number of subjects: 4152
Study 26942366 — intervention group
Group type: EXPERIMENTAL
Intervention: C perfringens presence
Number of subjects: 4152
Study 26942366 — intervention group
Group type: EXPERIMENTAL
Intervention: C sordellii follow-up
Number of subjects: 4152
Study 26942366 — intervention group
Group type: EXPERIMENTAL
Intervention: C perfringens follow-up
Number of subjects: 4152
Study 26942366 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent gynecologic surgery
Number of subjects: 4152
Study 26942366 — intervention group
Group type: EXPERIMENTAL
Intervention: High body mass index
Number of subjects: 4152
Study 26942366 — intervention group
Group type: EXPERIMENTAL
Intervention: C sordellii isolates
Number of subjects: 4152
Study 26942366 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain diversity
Number of subjects: 4152
Study 26942463 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzastaurin 500 mg orally once daily
Number of subjects: 25
Study 26942886 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched cohort (received no drugs predicted to be lack-of-benefit)
Number of subjects: 224
Study 26942886 — intervention group
Group type: COMPARATOR
Intervention: Unmatched cohort (received at least one drug predicted to be lack-of-benefit)
Number of subjects: 224
Study 26943275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and paclitaxel chemotherapy
Number of subjects: 40
Study 26943915 — intervention group
Group type: EXPERIMENTAL
Intervention: S-AR-42 administered via intravenous and oral routes in rodents
Number of subjects: 2
Study 26943915 — intervention group
Group type: EXPERIMENTAL
Intervention: R-AR-42 administered intravenously in rats
Number of subjects: 2
Study 26943915 — intervention group
Group type: EXPERIMENTAL
Intervention: S-AR-42 administered orally to tumor-bearing mice
Number of subjects: 2
Study 26944198 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic sacrocolpopexy
Number of subjects: 50
Study 26944482 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally mediated personal physician presence (facilitated access to the alcohol-reduction website)
Number of subjects: 620
Study 26944482 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 620
Study 26944694 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcirculatory parameters recorded using sublingual incident dark field microscopy and global flow measurements (oesophageal Doppler and transthoracic echocardiography).
Number of subjects: 0
Study 26944694 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Organ Failure Assessment scores analysis.
Number of subjects: 0
Study 26944863 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral LNG 1.5 mg plus LNG 52 mg IUD
Number of subjects: 188
Study 26944863 — intervention group
Group type: COMPARATOR
Intervention: Copper IUD
Number of subjects: 188
Study 26945556 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic confocal laser endomicroscopy (CLE) after medical treatment escalation
Number of subjects: 29
Study 26945556 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ulcerative colitis
Number of subjects: 29
Study 26945556 — intervention group
Group type: COMPARATOR
Intervention: Inactive ulcerative colitis and control subjects
Number of subjects: 29
Study 26945673 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic and psychological factors (KCNS1 and kinesiophobia)
Number of subjects: 150
Study 26945673 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic and psychological factors (ADRB2 and depressive symptoms)
Number of subjects: 150
Study 26945673 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic and psychological factors (GCH1 and anxiety symptoms)
Number of subjects: 150
Study 26945673 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory genes (IL6 SNPs and pain catastrophizing)
Number of subjects: 150
Study 26945673 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory genes (IL6 and depressive symptoms)
Number of subjects: 150
Study 26945843 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist (IL-1Ra)
Number of subjects: 47
Study 26945843 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist (IL-1Ra) + low-dose dexamethasone (20 mg weekly)
Number of subjects: 47
Study 26946139 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic segmentation of myocardium at risk (MaR) using contrast enhanced SSFP (CE-SSFP)
Number of subjects: 183
Study 26946139 — intervention group
Group type: COMPARATOR
Intervention: Manual delineation of myocardium at risk (MaR)
Number of subjects: 183
Study 26946139 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic segmentation of MaR using CE-SSFP
Number of subjects: 183
Study 26946139 — intervention group
Group type: COMPARATOR
Intervention: Manual delineation
Number of subjects: 183
Study 26946139 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic segmentation
Number of subjects: 183
Study 26946290 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C (one standard deviation increase)
Number of subjects: 0
Study 26946290 — intervention group
Group type: EXPERIMENTAL
Intervention: HMGCR (positive control)
Number of subjects: 0
Study 26946290 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9, APOB, LPA, CETP, PLG, NPC1L1, ALDH2 (identified druggable loci)
Number of subjects: 0
Study 26946891 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex ultrasound (DU)
Number of subjects: 66
Study 26947173 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat (200 mg)
Number of subjects: 20
Study 26947173 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (25 mg)
Number of subjects: 20
Study 26947173 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat and Warfarin
Number of subjects: 20
Study 26947199 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg/day, days 1-21 of a 28-day cycle (cohort 1)
Number of subjects: 14
Study 26947199 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg/day continuously (cohort 2)
Number of subjects: 14
Study 26947199 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 35 mg/day continuously (cohort 3)
Number of subjects: 14
Study 26947199 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (all cohorts)
Number of subjects: 14
Study 26947376 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal traction of ipsilateral arm
Number of subjects: 60
Study 26947376 — intervention group
Group type: COMPARATOR
Intervention: Abduction of ipsilateral arm
Number of subjects: 60
Study 26947376 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal traction of ipsilateral arm in adults
Number of subjects: 60
Study 26947376 — intervention group
Group type: COMPARATOR
Intervention: Neutral position of ipsilateral arm
Number of subjects: 60
Study 26947564 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaniprevir 300 mg twice daily plus pegylated interferon/ribavirin for 12 or 24 weeks
Number of subjects: 79
Study 26947564 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaniprevir treatment
Number of subjects: 79
Study 26948580 — intervention group
Group type: EXPERIMENTAL
Intervention: 140 mg semagacestat
Number of subjects: 15
Study 26948580 — intervention group
Group type: EXPERIMENTAL
Intervention: 280 mg semagacestat
Number of subjects: 15
Study 26948580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 26948683 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg dexamethasone suppression test (DST)
Number of subjects: 278
Study 26949046 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic phenotyping of plasma
Number of subjects: 233
Study 26949390 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous S(+)-ketamine infusion at a rate of 0.3 mg·kg(-1)·h(-1)
Number of subjects: 48
Study 26949390 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline at the same rate)
Number of subjects: 48
Study 26950065 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Number of subjects: 2433
Study 26950065 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily recombinant follicle stimulation hormone (rFSH)
Number of subjects: 2433
Study 26950065 — intervention group
Group type: COMPARATOR
Intervention: Control group (GnRH agonist protocol)
Number of subjects: 2433
Study 26950065 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG administration
Number of subjects: 2433
Study 26950065 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of follicles ≥ 11 mm and E2 levels
Number of subjects: 2433
Study 26951043 — intervention group
Group type: EXPERIMENTAL
Intervention: RebiSmart(®) for self-administering IFN β-1a 44 μg three times weekly
Number of subjects: 162
Study 26951310 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 or 10 mg/kg every 2 weeks or every 3 weeks
Number of subjects: 655
Study 26951310 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 655
Study 26951396 — intervention group
Group type: EXPERIMENTAL
Intervention: Orexin-A
Number of subjects: 63
Study 26951396 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 63
Study 26951410 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot gonadotropin-releasing hormone agonist (GnRHa) leuprolide
Number of subjects: 28
Study 26951410 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported nocturnal hot flashes
Number of subjects: 28
Study 26951410 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective hot flashes
Number of subjects: 28
Study 26951627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (100 mg once daily) combined with chemotherapy
Number of subjects: 51
Study 26951627 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib-based protocol
Number of subjects: 51
Study 26951635 — intervention group
Group type: EXPERIMENTAL
Intervention: GlycA (circulating N-acetyl glycan groups)
Number of subjects: 27524
Study 26951820 — intervention group
Group type: EXPERIMENTAL
Intervention: MRKAd5 HIV-1 Gag/Pol/Nef vaccine
Number of subjects: 0
Study 26951820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26951967 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD) patients
Number of subjects: 29
Study 26951967 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 29
Study 26952006 — intervention group
Group type: EXPERIMENTAL
Intervention: Resminostat plus sorafenib (n=38); dosages ranged from daily 200 to 600mg resminostat plus 400 to 800mg sorafenib.
Number of subjects: 57
Study 26952006 — intervention group
Group type: COMPARATOR
Intervention: Resminostat monotherapy (n=19); dosage was 600mg.
Number of subjects: 57
Study 26952546 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg, given every 3 weeks)
Number of subjects: 310
Study 26953688 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition processes
Number of subjects: 134
Study 26953688 — intervention group
Group type: EXPERIMENTAL
Intervention: Updating processes
Number of subjects: 134
Study 26953688 — intervention group
Group type: EXPERIMENTAL
Intervention: Shifting processes
Number of subjects: 134
Study 26953688 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition capacity
Number of subjects: 134
Study 26953688 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine dependence level
Number of subjects: 134
Study 26953733 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged 34-35 years
Number of subjects: 0
Study 26953733 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged 36-37 years
Number of subjects: 0
Study 26953733 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged 38-39 years
Number of subjects: 0
Study 26953733 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged 40-41 years
Number of subjects: 0
Study 26953733 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged 42-44 years
Number of subjects: 0
Study 26953733 — intervention group
Group type: COMPARATOR
Intervention: Women aged 30-31 years
Number of subjects: 0
Study 26953733 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with no prior pregnancy
Number of subjects: 0
Study 26953848 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab Q2W
Number of subjects: 3866
Study 26953848 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab Q4W
Number of subjects: 3866
Study 26953848 — intervention group
Group type: COMPARATOR
Intervention: Ixekizumab (both doses)
Number of subjects: 3866
Study 26953848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3866
Study 26954903 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain measures using Brief Pain Inventory Short Form (BPI-SF) and Short Form McGill Pain Questionnaire (SF-MPQ)
Number of subjects: 70
Study 26954903 — intervention group
Group type: EXPERIMENTAL
Intervention: Sino-Nasal Outcome Test (SNOT-22)
Number of subjects: 70
Study 26956588 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Measures
Number of subjects: 0
Study 26956588 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 26956723 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 25
Study 26957354 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral relaxation program
Number of subjects: 0
Study 26957532 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based medication use in-hospital and at discharge
Number of subjects: 76141
Study 26957532 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted 6-month mortality
Number of subjects: 76141
Study 26957532 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed 6-month mortality
Number of subjects: 76141
Study 26957532 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-myocardial infarction mortality
Number of subjects: 76141
Study 26958364 — intervention group
Group type: EXPERIMENTAL
Intervention: Multibiomarker disease activity (MBDA) score
Number of subjects: 220
Study 26958364 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 220
Study 26958364 — intervention group
Group type: COMPARATOR
Intervention: Low MBDA score
Number of subjects: 220
Study 26960231 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning scheme using mean diffusivity (MD) features and linear kernel SVMs
Number of subjects: 40
Study 26960790 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Number of subjects: 0
Study 26960977 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg adenosine injected into the left atrium
Number of subjects: 378
Study 26960977 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg adenosine injected sequentially after 20 mg
Number of subjects: 378
Study 26960977 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg adenosine injected sequentially after 20 mg
Number of subjects: 378
Study 26960977 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose adenosine
Number of subjects: 378
Study 26960977 — intervention group
Group type: EXPERIMENTAL
Intervention: Exit block test
Number of subjects: 378
Study 26961146 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib 400 mg monotherapy twice daily (capsule formulation)
Number of subjects: 300
Study 26961303 — intervention group
Group type: EXPERIMENTAL
Intervention: True Bipolar LV pacing
Number of subjects: 969
Study 26961303 — intervention group
Group type: COMPARATOR
Intervention: Unipolar/Extended Bipolar LV pacing
Number of subjects: 969
Study 26961932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling or bariatric surgery
Number of subjects: 184
Study 26962015 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with a smoker
Number of subjects: 1580
Study 26962015 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-hand smoke exposure in the past week
Number of subjects: 1580
Study 26962173 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake of 0.2 to 2.0 g ⋅ kg-1 ⋅ d-1, consumed hourly for 8 hours as an amino acid mixture with egg protein and L-[1-13C]phenylalanine as the indicator amino acid.
Number of subjects: 6
Study 26962173 — intervention group
Group type: COMPARATOR
Intervention: Current intake recommendations for dietary protein of 0.66 g ⋅ kg-1 ⋅ d-1 for EAR and 0.8 g ⋅ kg-1 ⋅ d-1 for RDA.
Number of subjects: 6
Study 26962176 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Inflammatory Index (DII) quartile 4
Number of subjects: 6542
Study 26962176 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Inflammatory Index (DII) quartile 4 in low-to-moderate alcohol drinkers
Number of subjects: 6542
Study 26962179 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B-6 restriction (0.37 ± 0.04 mg/d)
Number of subjects: 23
Study 26962183 — intervention group
Group type: EXPERIMENTAL
Intervention: α-lipoic acid (LA) 0.3 g/d
Number of subjects: 73
Study 26962183 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 1.3 g/d
Number of subjects: 73
Study 26962183 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 73
Study 26962189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa extract (1.4 g/d, 645 mg total polyphenols/d)
Number of subjects: 47
Study 26962189 — intervention group
Group type: COMPARATOR
Intervention: Control (no cocoa supplementation)
Number of subjects: 47
Study 26962193 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-LNSs with 0 or 10 mg added zinc and placebo tablet
Number of subjects: 2435
Study 26962193 — intervention group
Group type: COMPARATOR
Intervention: Control group (NIC)
Number of subjects: 2435
Study 26962194 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Nordic diet (n = 104)
Number of subjects: 200
Study 26962194 — intervention group
Group type: COMPARATOR
Intervention: Control diet (n = 96)
Number of subjects: 200
Study 26963600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 188
Study 26963600 — intervention group
Group type: COMPARATOR
Intervention: Behavior Therapy (BT)
Number of subjects: 188
Study 26963600 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Therapy (CT)
Number of subjects: 188
Study 26964824 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 26965168 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective admission (88 patients)
Number of subjects: 178